Related Experiment Videos
Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired
W D Creery1, A Hashmi, J S Hutchison
1Department of Pediatrics, University of Ottawa, Ontario, Canada.
Pediatric Pulmonology
|January 4, 1998
Insights
Pneumocystis pneumonia (PCP) can cause acute respiratory failure in children with HIV. Bovine lipid extract surfactant improved lung function in two infants with PCP and acute respiratory distress syndrome (ARDS).
Area of Science:
- Pediatric pulmonology
- Infectious diseases
- Critical care medicine
Background:
- Pneumocystis pneumonia (PCP) is a severe respiratory illness in children with HIV.
- PCP can lead to acute respiratory distress syndrome (ARDS) by disrupting lung surfactant.
- Current treatments for PCP/ARDS in children have limitations.
Observation:
- Two infants with acquired immunodeficiency syndrome (AIDS)-related PCP/ARDS presented with acute respiratory failure.
- Pulmonary function was assessed before and after intervention.
- The infants received bovine lipid extract surfactant.
Findings:
- Administration of bovine lipid extract surfactant led to improved pulmonary function in both infants.
- This suggests a potential benefit of exogenous surfactant in managing PCP/ARDS.
- The study highlights the role of surfactant dysfunction in PCP pathogenesis.
Implications:
- Bovine lipid extract surfactant may be a viable adjunctive therapy for pediatric PCP/ARDS.
- Further research is warranted to confirm efficacy and optimal dosing.
- This approach could improve outcomes for critically ill, HIV-infected children.
Abstract:
Pneumocystis carinii pneumonia (PCP) is an important cause of acute respiratory failure in HIV-infected children. PCP may initiate acute respiratory distress syndrome (ARDS) by adversely affecting surfactant physiology. We report improved pulmonary function following administration of bovine lipid extract surfactant to two infants with AIDS-related PCP/ARDS.